Am. J. Respir. Crit. Care Med., Volume 156, Number 6, December 1997, 1794-1799

Enhanced Thromboxane Biosynthesis in Patients with Chronic Obstructive Pulmonary Disease

GIOVANNI DAVÌ, STEFANIA BASILI, MARIO VIERI, FRANCESCO CIPOLLONE, STELLA SANTARONE, CESARE ALESSANDRI, PIERPAOLO GAZZANIGA, CORRADO CORDOVA, FRANCESCO VIOLI, and the Chronic Obstructive Bronchitis and Haemostasis Study Group

Istituto di Terapia Medica, Istituto di I Clinica Medica, Dipartimento di Medicina Sperimentale e Patologia, Istituto di Terapia Medica Sistematica, Università di Roma "La Sapienza", Rome; and Istituto Fisiopatologia Medica, Università di Chieti "G. D'Annunzio," Chieti, Italy

Thrombotic complications of pulmonary circulation occur in patients with chronic obstructive pulmonary disease (COPD). In the present study, we sought to evaluate in vivo platelet activation through the measurement of 11-dehydro-thromboxane (Tx) B₂, TxA₂ major metabolite in the urine, in 29 patients with COPD, compared with 29 sex- and age-matched healthy subjects. The urinary excretion of 11-dehydro-TxB₂ was significantly higher in patients with COPD than in control subjects: median (range), 753 (277-4,409) and 275 (129-612) pg/mg creatinine, respectively; p < 0.0001). Moreover, 11-dehydro-TxB₂ excretion was inversely related with arterial oxygen tension (rho = 0.46; p = 0.0145). In five of the 29 patients a short-term therapeutic course with oxygen supplementation induced a significant decrease of urinary 11-dehydro-TxB₂ excretion: median range, 941 (452-2,640) to 445 (166-1,560) pg/mg creatinine. Moreover, selective inhibition of platelet cyclooxygenase activity by low-dose aspirin was associated with more than 90% inhibition of thromboxane metabolite excretion, demonstrating its being of platelet origin. Plasma levels of prothrombin fragment F1+2 were higher in patients than in control subjects (2.6 ± 1.5 versus 0.9 ± 0.4 nM, p = 0.0001). No relation between 11-dehydro-TxB₂ excretion and plasma F1+2 levels was found. We conclude that platelet TxA₂ biosynthesis is enhanced in patients with COPD and may be influenced by arterial oxygen tension changes. Davì G, Basili S, Vieri M, Cipollone F, Santarone S, Alessandri C, Gazzaniga PP, Cordova C, Violi F, Chronic Obstructive Bronchitis and Haemostasis Study Group. Enhanced thromboxane biosynthesis in patients with chronic obstructive pulmonary disease.

This article has been cited by other articles:

				S. M. Wilson, P. Shen, C. F. Rider, S. L. Traves, D. Proud, R. Newton, and M. A. Giembycz Selective Prostacyclin Receptor Agonism Augments Glucocorticoid-Induced Gene Expression in Human Bronchial Epithelial Cells J. Immunol., November 15, 2009; 183(10): 6788 - 6799. [Abstract] [Full Text] [PDF]

				K. H. Groenewegen, D. S. Postma, W. C. J. Hop, P. L. M. L. Wielders, N. J. J. Schlosser, E. F. M. Wouters, and for the COSMIC Study Group Increased Systemic Inflammation Is a Risk Factor for COPD Exacerbations* Chest, February 1, 2008; 133(2): 350 - 357. [Abstract] [Full Text] [PDF]

				E. F. M. Wouters, K. H. Groenewegen, M. A. Dentener, and J. H. J. Vernooy Systemic Inflammation in Chronic Obstructive Pulmonary Disease: The Role of Exacerbations Proceedings of the ATS, December 1, 2007; 4(8): 626 - 634. [Abstract] [Full Text] [PDF]

				F. L. Fimognari, P. Pasqualetti, L. Moro, A. Franco, G. Piccirillo, R. Pastorelli, P. M. Rossini, and R. A. Incalzi The Association Between Metabolic Syndrome and Restrictive Ventilatory Dysfunction in Older Persons J. Gerontol. A Biol. Sci. Med. Sci., July 1, 2007; 62(7): 760 - 765. [Abstract] [Full Text] [PDF]

				R. Morchon, J. Lopez-Belmonte, A. Rodriguez-Barbero, and F. Simon High Levels of Serum Thromboxane B2 Are Generated during Human Pulmonary Dirofilariosis Clin. Vaccine Immunol., October 1, 2006; 13(10): 1175 - 1176. [Abstract] [Full Text] [PDF]

				I. C. Allen, J. M. Hartney, T. M. Coffman, R. B. Penn, J. Wess, and B. H. Koller Thromboxane A2 induces airway constriction through an M3 muscarinic acetylcholine receptor-dependent mechanism Am J Physiol Lung Cell Mol Physiol, March 1, 2006; 290(3): L526 - L533. [Abstract] [Full Text] [PDF]

				G. Cella, M. Saetta, S. Baraldo, G. Turato, A. Papi, G. Casoni, and M. Rigno Endothelial Cell Activity in Chronic Obstructive Pulmonary Disease Without Severe Pulmonary Hypertension Clinical and Applied Thrombosis/Hemostasis, October 1, 2005; 11(4): 435 - 440. [Abstract] [PDF]

				P. K. MacCallum Markers of Hemostasis and Systemic Inflammation in Heart Disease and Atherosclerosis in Smokers Proceedings of the ATS, April 1, 2005; 2(1): 34 - 43. [Abstract] [Full Text] [PDF]

				P. J. Barnes Mediators of Chronic Obstructive Pulmonary Disease Pharmacol. Rev., December 1, 2004; 56(4): 515 - 548. [Abstract] [Full Text] [PDF]

				E. Bohm, G. J. Sturm, I. Weiglhofer, H. Sandig, M. Shichijo, A. McNamee, J. E. Pease, M. Kollroser, B. A. Peskar, and A. Heinemann 11-Dehydro-thromboxane B2, a Stable Thromboxane Metabolite, Is a Full Agonist of Chemoattractant Receptor-homologous Molecule Expressed on TH2 Cells (CRTH2) in Human Eosinophils and Basophils J. Biol. Chem., February 27, 2004; 279(9): 7663 - 7670. [Abstract] [Full Text] [PDF]

				K. Kurokawa, H. Tanaka, S. Tanaka, and S. Abe Circadian Characteristics of Urinary Leukotriene E4 in Healthy Subjects and Nocturnal Asthmatic Patients Chest, December 1, 2001; 120(6): 1822 - 1828. [Abstract] [Full Text] [PDF]

				G. Cella, A. Sbarai, G. Mazzaro, B. Vanzo, S. Romano, D. Hoppensteadt, and J. Fareed Plasma Markers of Endothelial Dysfunction in Chronic Obstructive Pulmonary Disease Clinical and Applied Thrombosis/Hemostasis, July 1, 2001; 7(3): 205 - 208. [Abstract] [PDF]